Amicus Therapeutics is a young company which was created at the beginning of 2002. It is based in the city of Cranbury, New Jersey, and its industry is biopharmaceutics. The company currently has more than a hundred people in its workforce. The leader of the Amicus Therapeutics is Mr. John F. Crowley who is at the position of the chief executive officer (CEO). Mr. John F. Crowley has been the chief executive officer of Amicus Pharmaceuticals since the year of 2005. Five years later in 2010, Mr. John Crowly assumed the post of Chairman of the Board succeeding Mr. Donald Hayden, Jr.
Amicus Therapeutics has a focus on lysosomal storage disorders which is a collective term for a number of rare and orphan diseases. Amicus Therapeutics develops products through a system that vastly depends on the platform of CHART® – Chaperone-Advanced Replacement Therapy. This platform concentrates on the development of enzyme replacement therapies.
Over the years the company of Amicus Therapeutics has expanded through therapy development and acquisitions as well. The company indeed picked up the pace and was recognized a few years ago in 2014. It was noted for supposedly having one of broadest of portfolios in the industry regarding small molecule pharmacological chaperones. Amicus Therapeutics has been collaborating with some other companies such as Shire, JCR Pharmaceutical, GlaxoSmithKline, and more. Some of the partnerships lasted up to three years.
The acquisition of Amicus Therapeutics started up in 2013. That year was a winning one for Amicus Therapeutics as it acquired one of its competitors – Callidus Biopharma. That allowed Amicus Therapeutics to become a proprietor of the treatment for the Pompe Disease which is based on an enzyme replacement therapy. In September 2015, another acquisition followed. Amicus Therapeutics bought Scioderm for nearly a billion dollars as well as stock. That expanded Amicus Therapeutics and provided a clearer way ahead.
Amicus Therapeutics currently has a few medications on the market. The company mostly focuses on research. It expanded and set up another study site inSan Diego in 2008. The work was going smoothly up until the year, but after a while, the company was back on its feet and better than ever.